首页> 美国卫生研究院文献>Gut and Liver >High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

【2h】

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

机译：平剂量利巴韦林加Sofosbuvir / Daclatasvir在基因型3肝硬化患者中的高疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir (DCV)/sofosbuvir (SOF) plus a flat dose of 800 mg RBV (flat dose) compared to DCV/SOF without RBV or DCV/SOF plus an RBV dose based on body weight (weight-based) in G3-HCV patients with compensated or decompensated cirrhosis.

机译：与其他HCV基因型的患者相比，基因3型丙型肝炎病毒（G3-HCV）肝硬化的患者非常难以治疗。与利巴韦林（RBV）相关的最佳治疗持续时间和药物治疗方案尚不清楚。为了评估达卡他韦（DCV）/索非布韦（SOF）加上800毫克RBV的统一剂量（平坦剂量）与不使用RBV的DCV / SOF或DCV / SOF加上基于体重的RBV剂量的疗效和安全性G3-HCV肝硬化代偿或代偿失调患者）。

著录项

期刊名称 Gut and Liver
作者
Adriano Pellicelli; Vincenzo Messina; Valerio Giannelli; Marco Distefano; Valeria Pace Palitti; Pascal Vignally; Pierluigi Tarquini; Antonio Izzi; Alessandra Moretti; Sergio Babudieri; Serena Dell’Isola; Massimo Marignani; Gaetano Scifo; Vincenzo Iovinella; Giuseppe Cariti; Maurizio Pompili; Francesco Di Candilo; Luca Fontanella; Giuseppe M. Ettorre; Giovanni Vennarecci; Antonio Massimo Ippolito; Giorgio Barbarini; for the Working Group CLEO;
展开▼
作者单位

展开▼
年(卷),期 2020(14),3
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词
Daclatasvir; Cirrhosis; liver; Genotypes 3; Hepatitis C; Drug therapy; Ribavirin;

机译：达拉他韦;肝硬化;肝;基因型3;丙型肝炎;药物治疗;利巴韦林;

相似文献

外文文献
中文文献
专利

1. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients [J] . Adriano Pellicelli, Vincenzo Messina, Valerio Giannelli, Gut and Liver . 2020,第3期

机译：扁平剂量利巴韦林加Sofosbuvir / daclatasvir在基因型3肝硬化患者的高疗效和安全性
2. P1‐092: The efficacy of sofosbuvir/velpatasvir/ribavirin in cirrhotic, genotype 3a HCV patients, previously failures to sofosbuvir/daclatasvir/ribavirin combination [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P1-092：Sofosbuvir / VelpataSvir /利巴韦林在肝硬化，基因型3A HCV患者中的疗效，以前对Sofosbuvir / daclatasvir /利巴韦林组合的故障
3. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV [J] . Zeng Q. -L., Li C. -X., Zhang D. -W., Alimentary pharmacology & therapeutics. . 2016,第7期

机译：信：索非布韦联合达卡他韦联合利巴韦林在中国治疗经验丰富的肝硬化基因型1b HCV患者中安全性和有效性12周
4. Efficacy of combination therapy of interferon-α and ribavirin for HIV/HCV co-infected patients in a six-year follow-up [C] . AiPing Wang, ChunYang Wen, Fang Gao 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：六年随访中干扰素-α和利巴韦林联合治疗对HIV / HCV合并感染患者的疗效
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice [O] . Luis Margusino-Framiñán, Purificación Cid-Silva, Álvaro Mena-de-Cea, 2020

机译：达卡他韦/索非布韦联合利巴韦林或不联合利巴韦林在基因型3型丙型肝炎病毒感染患者中的有效性和安全性。实际临床实践中的结果
7. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients [O] . Adriano Pellicelli, Vincenzo Messina, Valerio Giannelli, 2020

机译：扁平剂量利巴韦林加Sofosbuvir / daclatasvir在基因型3肝硬化患者的高疗效和安全性

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅